Introduction {#S0001}
============

In healthy humans, the oral cavity is colonized by numerous microbial species.[@CIT0001],[@CIT0002] *Candida* species are commensals that can be found in the oral tract of 15.2--75% of healthy individuals.[@CIT0002]--[@CIT0005] However, a number of external and internal factors can lead to host-fungus unbalance, which results in yeast overgrowth and potential oropharyngeal candidiasis (OPC). OPC is frequently observed in patients with HIV/AIDS, malignancy, diabetes mellitus, and in patients with solid organ transplants or those who are prescribed antibiotics. Hence, immunocompromised patients are predisposed to developing refractory and recurrent episodes of OPC, which may be severe and be associated with disease progression.[@CIT0002],[@CIT0003],[@CIT0005]--[@CIT0009]

Many of such patients with refractory and recurrent OPC are exposed to repeated courses of antifungal therapy which poses a risk for emergence of drug-resistant yeast isolates. *Candida* species can cause a variety of lesions in the oral cavity including pseudomembranous and erythematous lesions, angular cheilitis and median rhomboid glossitis. These can be irritative and painful and impact digestion and absorption of food, with subsequent systemic infection, especially in immunocompromised patients.[@CIT0010]--[@CIT0012] *Candida albicans* remains the most causative pathogen, although non-*C. albicans Candida* species, such as *C. tropicalis, C. krusei, C. parapsilosis*, and *C. glabrata*, have played an increasing role.[@CIT0002],[@CIT0009]

OPC is treated with either topical or systemic antifungal agents with polyenes and azole antifungal agents being the most frequently used. Hence, in settings where for example, azole resistance is emergent, selection of antifungal therapy is challenging.[@CIT0001],[@CIT0002],[@CIT0013],[@CIT0014] In Africa, the resistance rate of *Candida* isolates to azoles in Ethiopian HIV-infected patients with OPC has ranged from 1.3% to 12.3% depending on the azole antifungal agent[@CIT0002]

Local data including species distribution and the antifungal susceptibility profile of fungal species causing OPC is essential as these data cannot be generalized across countries. In China, data on the relative frequency of *C. albicans* vs non-*albicans Candida* species as etiologic agents of OPC and that on drug resistance of OPC isolates of *C. albicans* to the currently available antifungals are few.[@CIT0011],[@CIT0015] The present multicenter study aimed to determine the trend of the species distribution and antifungal susceptibility patterns of yeast isolates obtained from refractory and recurrent OPC collected from a large number of hospitals in China.

Materials and methods {#S0002}
=====================

Ethics statement {#S0002-S2001}
----------------

The study was approved by the Human Research Ethics Committee of Peking Union Medical College Hospital (PUMCH) (No. S-263). Written informed consent was obtained from all patients in the study for permission to study the isolates cultured from them for scientific research.

Clinical isolates {#S0002-S2002}
-----------------

A total of 558 non-duplicate *Candida* isolates from 535 patients with refractory or recurrent OPC were included over the study period, October 1, 2013 to April 30, 2016. Patients were from eleven different hospitals in seven provinces in China. The definition of refractory or recurrent OPC was infection that has recurred or persisted after at least one treatment course with an appropriate antifungal agent[@CIT0016]

Laboratory procedures {#S0002-S2003}
---------------------

### Species identification {#S0002-S2003-S3001}

At each study site, specimens were obtained by swabbing the oropharyngeal mucosa with a sterile swab, which was then were plated onto Sabouraud's dextrose agar (SDA) (bioMérieux, France) and incubated at 37°C for 48 hrs. Isolates were also inoculated onto CHROMagar *Candida* medium (CHROMagar, Paris, France). The initial species identification result was obtained by morphological appearance on CHROMagar *Candida* medium (CHROMagar) and by using the VITEK 2® compact system (BioMérieux, Marcyl' Etoile, France). Species identification (final identification result) was confirmed at a reference mycology facility at the PUMCH, Beijing, China using Bruker Biotyper matrix-assisted laser desorption ionization-time of flight mass spectroscopy (MALDI-TOF MS) system (Biotyper version 3.1 software, Bruker Daltonics, Billerica, USA) supplemented by DNA sequencing of the fungal internal transcribed spacer (ITS) region,[@CIT0017] where MALDI-TOF MS identification produced a log score of \<2.0.

In brief, for ITS sequencing, DNA extraction was performed using beating protocol and amplification of the ITS region was carried out with the primer pairs ITS1 (5ʹ-TCC GTA GGT GAA CCT GCG G-3ʹ) and ITS4 (5ʹ-TCC TCC GCT TAT TGA TAT GC-3ʹ) as described by Zhang et al[@CIT0018] The PCR products were purified with QIAquick PCR Purification Kit (QIAGEN, Germany), then sequenced in both directions using corresponding PCR amplification primer pairs at Ruibiotech Co. Ltd. (Beijing, China) using the DNA analyzer ABI 3730XL system (Applied Biosystems, Foster City, CA). Species identification was performed by comparing the obtained sequences against GenBank database with nucleotide Basic Local Alignment Search Tool (BLASTn, <http://blast.ncbi.nlm.nih.gov>).

### Antifungal susceptibility testing {#S0002-S2003-S3002}

*Candida* species will be allowed antifungal susceptibility testing after 24 hrs of incubation in the ambient air atmosphere at 35°C in SDA. In vitro susceptibility testing of all isolates to fluconazole, voriconazole, itraconazole, miconazole, ketoconazole, amphotericin B, nystatin and 5-ﬂucytosine were performed by broth microdilution methodology according to the Clinical and Laboratory Standards Institute (CLSI) M27-A3 protocol[@CIT0019] The minimum inhibitory concentration (MIC) for amphotericin B and nystatin was read as the lowest concentration that resulted in no discernible growth following 24 hrs of incubation. For 5-ﬂucytosine and the azoles, approximately 50% reduction in growth relative to the drug-free growth control was considered as the MIC endpoint. *C. parapsilosis* ATCC 22019 and *C. krusei* ATCC 6258 were the quality control strains for each test run[@CIT0019] The final range of concentrations tested was: 0.015--16 μg/mL for amphotericin B, miconazole, itraconazole, voriconazole, nystatin and ketoconazole, 0.06--64 μg/mL for 5-ﬂucytosine and 0.125--128 μg/mL for fluconazole. All experiments were performed in duplicate and on two separate occasions.

MIC results were interpreted by species-specific clinical breakpoints (CBPs) as recommended by the CLSI M60 method[@CIT0020] With regard to species for which there are no CBPs, we used epidemiological cutoff values (ECVs) to differentiate wild-type (WT) from non-WT isolates according to CLSI M59 method[@CIT0021] and ECVs from the study by Pfaller et al[@CIT0022] MIC results in miconazole, nystatin, and ketoconazole were defined using an arbitrary breakpoint as previously described.[@CIT0023]--[@CIT0025] The CBPs and ECV against common *Candida* species used in this study summarized in [Table S1](#ST0001).

Results {#S0003}
=======

Species distribution and patient characteristics {#S0003-S2001}
------------------------------------------------

A total of 558 *Candida* isolates comprising ten species were confirmed as causative pathogens at the reference laboratory. *C. albicans* was the most frequently isolated species accounting for 500 (89.6%) of isolates, followed by *C. glabrata*, 29 (5.2%), *C. tropicalis*, 16 (2.9%), *C. parapsilosis*, 4 (0.7%), *C. krusei*, 2 (0.4%), and other *Candida* species, 7 (1.2%).

In the present study, 76% of isolates were isolated from females and 24%, in males. Isolation of *Candida* isolates varied with age which increased from a frequency of 8.7% (patients aged 20--39 years) to 54.3% (patients aged≥60 years). [Table 1](#T0003){ref-type="table"} summarizes the patient characteristics, and the geographical distribution of infection is presented in [Figure 1](#F0001){ref-type="fig"}.Table 1Clinical characteristics of patients with refractory and recurrent oropharyngeal candidiasis and species distribution of the *Candida* isolatesPatient characteristicNumber (%) of isolatesTotal*C. albicansC. glabrata* complex*C. tropicalisC. parapsilosis*Others**Age (years)**20--3949 (8.7)44211140--59206 (37)1867823≥60303 (54.3)27020715**Gender**Male134 (24)11310524Female424 (76)387191125Total558 (100)500 (89.6)29 (5.2)16 (2.9)4 (0.7)9 (1.6) Figure 1Geographical distribution of *Candida* isolates causing refractory and recurrent oral candidiasis collected in this study. The two letters are the abbreviation of the hospitals that participated in this program, and the full hospital name can be found in the Acknowledgments section. The number in parentheses represents the number of isolates collected from the corresponding hospital, the percentage in parentheses represent the number of isolates from the corresponding hospital as a percentage of the total.

Twenty-one patients suffered mixed oropharyngeal yeast infections with *C. albicans* cultured in almost all (95.2%) mixed infections, except in one episode caused by *C. guilliermondii* and *C. parapsilosis*. Mixed infections caused by three yeasts were those of *C. albicans* with *C. glabrata* and *C. tropicalis* in two patients. Amongst infections caused by two yeasts, *C. albicans* featured in eleven patients with *C. glabrata*, in two patients with *C. tropicalis* and in one patient with *C. parapsilosis, C. guilliermondii, C. carpophila, C. lusitaniae*, and *C. norvegensis* (see [Table S2](#ST0002) for summary).

Agreement between initial and final identification results {#S0003-S2002}
----------------------------------------------------------

The agreement of identification results for yeasts obtained from participating hospitals and the reference laboratory is showed in [Table 2](#T0004){ref-type="table"}. Overall agreement was 91.2% (509/558 isolates) with the highest agreement observed for *C. albicans* (486/500, 97.2% isolates). However, for other *Candida* species, the identification agreement was substantially lower (0--57.2%).Table 2Comparison of identification results of the 558 *Candida* isolates between those obtained from participating hospitals (initial identification) and those obtained from the central laboratory (final identification)Species of final identificationNo. of isolatesAgreement between initial and final identificationNumber (%) of isolates with agreementNumber (%) of isolates with identification errorsMajorMisidentification (number)MinorMisidentification (number)*C. albicans*500486 (97.2%)12 (2.4%)*C. glabrata* (5)\
*C. tropicalis* (7)2 (0.4%)*Candida* spp. (2)*C. glabrata*2916 (55.2%)12 (41.4%)--1 (3.4%)--*C. glabrata* sensu stricto2816 (57.2%)12 (42.8%)*C. albicans* (9)\
*C. tropicalis* (2)\
*C. krusei* (1)0--*C. nivariensis*100--1 (100%)*C. glabrata* (1)*C. tropicalis*164 (25%)12 (75%)*C. albicans* (11)\
*C. glabrata* (1)0--*C. parapsilosis*41 (25%)3 (75%)--0--*C. parapsilosis* sensu stricto31 (33.3%)2 (66.7%)*C. tropicalis* (1)\
*C. krusei* (1)0--*C. orthopsilosis*101 (100%)*C. albicans* (1)0--*C. krusei*22 (100%)0--0--*C. lusitaniae*201 (50%)*C. krusei* (1)1 (50%)*Candida* spp. (1)*C. guilliermondii*201 (50%)*C. krusei* (1)1 (50%)*Candida* spp. (1)*C. norvegensis*101 (100%)*C. albicans* (1)0--*C. carpophila*101 (100%)*C. glabrata* (1)0--*C. pelliculosa*101 (100%)*C. glabrata* (1)0--Total558509 (91.2%)44 (7.9%)5 (0.9%)[^2]

Incorrect identification to species level by conventional methods included those identified through the use of CHROMagar *Candida* medium and VITEK 2® compact system and varied with species of *Candida: C. albicans* (12/500, 2.4%), *C. glabrata* sensu stricto (12/28, 42.8%), *C. tropicalis* (12/16, 75%), *C. parapsilosis* (3/4, 75%) and six other species (7/9, 77.8%) including *C. krusei* (2/2), *C. lusitaniae* (0/2,100%), *C. guilliermondii* (0/2,100%), *C. norvegensis* (0/1,100%), *C. carpophila* (0/1,100%), and *C. pelliculosa* (0/1,100%). Among 12 *C. albicans* isolates, five isolates were misidentified to *C. glabrata* sensu stricto and seven, to *C. tropicalis*. Moreover, nine *C. glabrata* sensu stricto isolates and eleven *C. tropicalis* isolates were incorrectly identified as *C. albicans*. Almost all uncommon *Candida* species were incorrectly identified. Further, minor errors occurred in five isolates (0.9%) including four species ([Table 2](#T0004){ref-type="table"}).

Antifungal susceptibilities {#S0003-S2003}
---------------------------

The susceptibility results for causative *Candida* species are shown in [Table 3](#T0005){ref-type="table"}. Most azoles drugs were highly active against *C. albicans*. For miconazole, the MIC~50~ and MIC~90~ values were 0.125 and 0.5 μg/mL, respectively, and 488/500 isolates (97.6%) were susceptible to this drug. Fluconazole and voriconazole had comparable activity against *C. albicans*, where 96% and 95.8%, respectively were susceptible to these drugs. Two fluconazole-resistant *C. albicans* isolates were also resistant to voriconazole. For *C. glabrata*, the MIC~50~ of fluconazole was 16 μg/mL and all *C. glabrata* isolates were susceptible-dose dependent. Except for ketoconazole (with the percentage of non-wild type of 37.9%), all isolates of *C. glabrata* were susceptible to the other antifungal drugs. One of 16 isolates (6.2%) of *C. tropicalis* was resistant to fluconazole, voriconazole, and miconazole, with MIC of 128, 8, and 16 μg/mL, respectively. Only one (25%) *C. parapsilosis* isolate was resistant to all the azole drugs, *C. albicans* showed a high non-susceptibility rate (67.2%) against itraconazole, which was much higher than that of other *Candida* species with the percentage of wild type from 75% to 100%.Table 3Antifungal susceptibility results of 558 isolates to eight antifungal agentsOrganism and antifungal agentRange (μg/mL)MIC~50~MIC~90~%S/%WT%R/%NWT*C. albicans* (n=500）Fluconazole≤0.125--6412961.4Voriconazole≤0.015--40.030.12595.80.4Itraconazole≤0.015--10.250.532.83Miconazole≤0.015-\>160.1250.597.62.4Ketoconazole≤0.015--10.030.12590.60.4Amphotericin B≤0.015--41299.40.6Nystatin≤0.015--42410005-Flucytosine≤0.064--10.1250.2599.80.2*C. glabrata* (n=29)Fluconazole0.25--161616--0Voriconazole0.03--0.50.50.572.427.6Itraconazole0.125--2121000Miconazole0.03--20.521000Ketoconazole0.03--20.5224.137.9Amphotericin B≤0.015--2121000Nystatin1--42210005-Flucytosine≤0.064--0.125≤0.0640.1251000*C. tropicalis* (n=16)Fluconazole0.25--1280.56493.86.2Voriconazole≤0.015--80.03893.86.2Itraconazole0.125--0.50.250.51000Miconazole≤0.015--160.25893.86.2Ketoconazole≤0.015--0.50.0640.587.50Amphotericin B1--2221000Nystatin0.125--21210005-Flucytosine≤0.064≤0.064≤0.0641000*C. parapsilosis* (n=4)Fluconazole0.5--8117525Voriconazole0.03--0.50.030.064750Itraconazole0.25--10.50.57525Miconazole1--2117525Ketoconazole0.03--0.250.0640.064750Amphotericin B0.5--2111000Nystatin1--22210005-Flucytosine≤0.064--0.250.0640.0641000Other species (n=9)Fluconazole0.25--16816----Voriconazole≤0.015--0.50.250.5----Itraconazole0.03--10.51----Miconazole0.064--424----Ketoconazole≤0.015--10.251----Amphotericin B0.5--414----Nystatin0.125--212----5-Flucytosine≤0.064--40.1252---- Table 4Review about the species distribution of yeast species obtained from OPC and IFI patientsStudiesNo. of hospitalsRegionNo. of isolates*C. albicansC. glabrataC. tropicalisC. parapsilosis*Other speciesRef.***Invasive fungal infections***CHIF-NET65China8,82944.910.817.2207.1Xiao et al[@CIT0028]BJ-NET28China\
(Beijing only)1,20150.315.113.313.47.9Guo et al[@CIT0029]ARTEMIS133Worldwide19,761965.311.37.26.010.2Pfaller et al[@CIT0030]***Oropharyngeal candidiasis***OPC 11Japan15472.823.41.91.30.6Kamikawa et al[@CIT0031]OPC 21UK61884.39.52.11.92.2Kuriyama et al[@CIT0026]OPC 31China\
(Hainan only)31354.321.712.5110.5Wu et al[@CIT0011]OPC 41China (Yunnan only)32082.29.10.63.84.3Li et al[@CIT0015]OPC 51Tanzania29684.56.82.706Hamza et al[@CIT0027]Present study11China55889.65.22.90.71.6Yu et al

The MIC~50~ values of uncommon *Candida* species were at least three folds higher than those of *C. albicans* for fluconazole, voriconazole, miconazole, and ketoconazole; for itraconazole the MIC~50~ was only one dilution higher. Compared to the azoles, amphotericin B, nystatin and 5-ﬂucytosine had greater in vitro activity against these species. The susceptibility rates to these three drugs reached up to 100% for *C. glabrata, C. tropical,* and *C. parapsilosis* isolates. However, three *C. albicans* isolates were considered resistant to amphotericin B and one isolate had non-WT MICs to 5-ﬂucytosine. Of 58 non-*C. albicans Candida* isolates, the MIC~50~ and MIC~90~ values of fluconazole, voriconazole, ketoconazole, and miconazole were two to three folds as high as of those of *C. albicans*. In comparison, MIC~50~ values for amphotericin B, nystatin and 5-ﬂucytosine were very similar between non-*C. albicans* species and *C. albicans*. Ketoconazole had the lowest MIC~50~ and MIC~90~ values, with nearly two folds lower values than those of itraconazole and miconazole in *C. albicans* although miconazole had higher susceptibility rate.

Discussion {#S0004}
==========

Refractory or recurrent episodes of OPC result in increased morbidity and reduced quality of life. Their targeted management relies on accurate epidemiological surveillance data to determine whether current empirical treatments are appropriate. However, no contemporary large-scale surveillance studies of OPC have been performed in China to determine species distribution and if there are any variations in antifungal susceptibilities of causative yeast species, particularly in patients who are repeatedly exposed to antifungal agents.

Our finding of *C. albicans* as the predominant species (89.6%), and *C. glabrata* (5.2%) and *C. tropicalis* (2.9%) as the next most common *Candida* species, are consistent with the assessments made in similar studies of the in vitro susceptibility of oropharyngeal *Candida* isolates from UK patients and Tanzanian HIV-infected patients.[@CIT0026],[@CIT0027] The main *Candida* species were *C. albicans* (521 isolates, 84.3%), *C. glabrata* (59 isolates, 9.5%), and *C. tropicalis* (13 isolates, 2.1%) in the UK study and *C. albicans* (250 isolates, 84.5%), *C. glabrata* (20 isolates, 6.8%), and *C. tropicalis* (8 isolates, 2.7%) in the Tanzanian study.[@CIT0026],[@CIT0027]The frequency of *C. albicans* isolates in our study is also similar to that found among hospitalized patients in Kunming (82.2%) in a prior study,[@CIT0015] but conversely, much lower (54.3%) than that compared to another study conducted in Hainan.[@CIT0011] In addition, it has been observed the frequencies of *C. albicans* in three large-scale studies of invasive fungal infections (IFIs) studies were much lower than our study's with infection rate from 34.6% to 65.3%.[@CIT0028]--[@CIT0030] Thus, our study suggests that *C. albicans* still remains the predominant species in OPC patients. The species distribution of yeast species obtained from OPC and IFI patients are summarized in [Table 4](#T0004){ref-type="table"}. [@CIT0015],[@CIT0026]--[@CIT0031]

Incorrect species identification results by the CHROMagar *Candida* medium and the VITEK 2® compact system not only occurred with the uncommon *Candida* isolates (1.3%), but also amongst common *Candida* species (7.5%). It is well known that CHROMagar *Candida* medium and the VITEK 2® compact system have limitations for the identification of certain *Candida* species. CHROMagar *Candida* medium can only identify a few *Candida* species including *C. albicans* (colored green), *C. tropicalis* (dark blue), and *C. krusei* (pink and downy appearance)[@CIT0032] Likewise, certain common yeasts cannot be identified by the Vitek 2® compact system (biomerieux)[@CIT0033] Moreover, mixed infections such as that in the present study, can pose a challenge in both the diagnosis and treatment of refractory and recurrent OPC. Incorrect identification will greatly affect the choice of antifungal agent, so accurate identification by MALDI-TOF MS and/or ITS sequencing is essential to confirm any unusual species identifications or where more than one species may be present.

Of note, compared with previous studies which have mainly included OPC patients who had not received previous antifungal treatment, in our study, we have observed reduced susceptibility to all antifungal agents for the majority *Candida* species.[@CIT0011],[@CIT0015],[@CIT0026],[@CIT0027] For the predominant species, *C. albicans*, the MIC~50~ values of fluconazole, voriconazole, itraconazole, miconazole, and ketoconazole were 1 , 0.03 , 0.25 , 0.12 , and 0.03 μg/mL, respectively. These values are higher than those reported by Kuriyama et al, which found for patients who had not received previous antifungal therapy, MIC~50~ values for fluconazole, voriconazole, itraconazole, miconazole, and ketoconazole of 0.25 , 0.015 , 0.06 , 0.03 , and 0.03 μg/mL, respectively. Because of different breakpoints or ECVs employed in our, and the above study, we are not able to compare the rates of resistance or frequency of non-WT isolates. The MIC~50~ values in our study cohort suggest that prior exposure to azoles and other antifungal agents, predisposes to the risk of reduced susceptibility to antifungal agents as observed before.[@CIT0026],[@CIT0027]

Itraconazole is an important antifungal agent for OPC treatment in China. In a previous study,[@CIT0034] long-term itraconazole prophylaxis was associated with reduction in susceptibility to itraconazole and cross-resistance to ﬂuconazole in mucosal *C. albicans* from patients with AIDS. This may explain why the *Candida* isolates showed reduced susceptibility to azoles in our study. According to the ESCMID guidelines for management of OPC,[@CIT0035] fluconazole remains the preferred antifungal drug. Miconazole, itraconazole, voriconazole are potential alternatives to fluconazole but itraconazole has a higher incidence of unreliable oral bioavailability and drug--drug interactions compared with fluconazole. The use of itraconazole may also be complicated by cross-resistance to fluconazole.[@CIT0036] Therefore, regular monitoring of serum drug levels is required.

Even though miconazole has a higher MIC breakpoint in comparison with other azoles,[@CIT0023] it still was the most active azole for *C. albicans*. Miconazole may be administered as a topical agent. Various topical formulations including miconazole buccal tablets, miconazole chewing gum, miconazole oral gel, and miconazole lacquer have been used to treat oral candidiasis. Hence, miconazole may be considered alternate regimen for OPC in countries where topical miconazole is used[@CIT0013]

Of note, 1.4% *C. albicans* isolates were resistant to fluconazole, slightly higher than the rate of resistance found in the China Hospital Invasive Fungal Surveillance Net study (resistance rate 0.5%). Based on our data, itraconazole and miconazole established great antifungal activity to *C. glabrata* with 100% susceptibility rate, while the susceptibility rate of voriconazole and ketoconazole was relatively low. We also found one of 16 isolates of *C. tropicalis* and one out of four isolates of *C. parapsilosis* to be resistant to all azoles. Azole resistance amongst *Candida* spp. are usually attributed to selection pressure caused by prior exposure antifungal agents and cumulative doses of azoles[@CIT0027] Whilst there are no interpretative breakpoint criteria for amphotericin B, nystatin and 5-ﬂucytosine, the present study has shown that MICs for miconazole, amphotericin B, nystatin and 5-ﬂucytosine were within a narrow range consistent with a previous study[@CIT0027]

Two main limitations of this study are mentioned herein. Firstly, we did not collect data on patient underlying disease, drug history, antifungal treatment and outcomes of refractory, and recurrent OPC. Further, the present survey focused only on centers located in seven provinces of China. Extending coverage of the study to the whole country would be significant for continued surveillance.

In conclusion, the present study provides valuable surveillance data on the species distribution and antifungal susceptibility of a large number of oropharyngeal yeast isolates collected from geographically diverse areas of China. Significantly reduced susceptibility to all the azoles was observed form patients with recurrent OPC. *C. albicans* is still the most frequently isolated species but has elevated MICs to the azoles. In contrast, miconazole, amphotericin B, nystatin, and 5-ﬂucytosine have retained high antifungal activity. For adequate therapy, efforts must be maintained to carry out accurate and timely identification and antifungal susceptibility testing.
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Table S1The clinical breakpoints and epidemiological cutoff values ^(18−23)^ against common *Candida* species used in this studyMIC CBPsMIC ECVSI/SDDRWTNon-WTFLZ*C. albicans*≤24≥8*C. glabrata complex*--≤32≥64*C. tropicalis*≤24≥8*C. parapsilosis complex*≤24≥8VOR*C. albicans*≤0.0120.25-0.5≥1*C. glabrata complex*≤0.25\>0.25*C. tropicalis*≤0.0120.25-0.5≥1*C. parapsilosis complex*≤0.0120.25-0.5≥1ITR*C. albicans*≤0.120.25-0.5≥1*C. glabrata complex*≤4\>4*C. tropicalis*≤0.5\>0.5*C. parapsilosis complex*≤0.5\>0.5MCZ≤1≥2KCZ≤0.06250.125-0.5≥1AMB≤2\>2NYS≤48-32≥645-FC≤0.5\>0.5 Table S2The cases of 21 patients suffered mixed oropharyngeal yeast infections summarizedNo. of patientsMixed infections11*C. albicans+C. glabrata*2*C. albicans+C. glabrata+C. tropicalis*2*C. albicans+C. tropicalis*1*C. albicans+C. parapsilosis*1*C. albicans+C. guilliermondii*1*C. albicans+C.carpophila*1*C. albicans+C. lusitaniae*1*C. albicans+C. norvegensis*1*C. guilliermondii + C. parapsilosis*

[^1]: These authors contributed equally to this work

[^2]: **Note:** \*A minor error of identification of the isolate was defined as correct identification of an isolate to the genus level but inability to identify it to the species level (eg, *C. albicans* identified as *Candida* spp.) or initial correct identification of an isolate to the level but not to the species level (eg, *C. metapsilosis* or *C. orthopsilosis* identified as *C. parapsilosis* and *C. nivariensis* as *C. glabrata*). A major error was defined as other disagreements between the initial identification and the final identification.
